This study is a multicenter, open-label, non-randomized study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with Non-Segmental Vitiligo
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
VC005 repeat administration for up to 24 weeks
The Peking University People's Hospital
Beijing, Beijing Municipality, China
Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC)
Time frame: Day1,Day28
Peak Plasma Concentration (Cmax)
Time frame: Day1,Day28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.